Last edition
News about "FSGS"
Travere Therapeutics Receives USPTO Patent Allowance for Filspari Use in IgA Nephropathy
Travere Therapeutics has secured a Notice of Allowance from the USPTO for a patent application covering specific methods of using Filspari (sparsentan) in the treatment of IgA nephropathy, strengthening its rare kidney disease portfolio.
FSGS | 29/05/2026 | By News Bureau | 138
Phase II data show apecotrep, a first-in-class oral TRPC6 inhibitor, significantly reduced proteinuria in patients with primary FSGS, supporting ongoing Phase III development.
FSGS | 29/01/2026 | By News Bureau | 231
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy